A new multicenter study, led by David Leppert, Roberto Furlan, and Jens Kuhle, demonstrates that measuring specific markers in cerebrospinal fluid can accurately differentiate MOG-antibody disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and multiple sclerosis (MS).
By analyzing granulocyte activation markers (GAM), astrocyte damage markers (ADM), and complement factors (C5/C5a), the research team established a fast and precise, biology-driven approach to support diagnosis in acute demyelinating events.
Key Highlights
- GAM and ADM levels peak during acute MOGAD and NMOSD, but not in MS.
- MMP-9 remains elevated in MS, distinguishing it from MOGAD and NMOSD.
- Combined biomarker panels achieved AUC values up to 0.925 for differentiating MOGAD from MS.
- GAM and C5/C5a correlated with neurological impairment, underscoring their role in neural damage.
These findings open new avenues for timely and targeted treatment of inflammatory demyelinating diseases and complement existing antibody-based diagnostics.
Congratulations to the authors and their teams for leading this impactful international collaboration.
Full article: https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaf345/8262628?login=false
